Middle East And Africa Bladder Disorders Market
市场规模(十亿美元)
CAGR :
%

![]() |
2022 –2029 |
![]() |
USD 327.73 Million |
![]() |
USD 519.60 Million |
![]() |
|
![]() |
>中东和非洲膀胱疾病市场,按类型(膀胱炎、尿失禁、膀胱过度活动症、间质性膀胱炎、膀胱癌)、治疗类型(手术、药物、非手术)、最终用户(医院、诊所、门诊手术中心、其他)、分销渠道(直接、零售)划分 - 行业趋势和预测到 2029 年。
中东和非洲膀胱疾病市场分析和见解
膀胱疾病是一组会影响人类日常生活的疾病。最常见的膀胱疾病包括膀胱炎(膀胱感染并引起炎症)。尿失禁(失去膀胱控制)、间质性膀胱炎(膀胱疼痛和频繁、紧迫排尿)和膀胱过度活动症(膀胱挤压尿液的一种情况)。膀胱疾病会影响生活质量并导致其他健康问题。健康变化和问题(包括神经系统和生活方式因素)可能导致或加剧男性和女性的 UI。
最常见的膀胱疾病是膀胱过度活动症和尿路感染。这些问题与神经系统有关。神经将信息从大脑传递到膀胱,指示肌肉收缩或释放。
预计中东和非洲膀胱疾病市场将在 2022 年至 2029 年的预测期内增长。Data Bridge Market Research 分析称,在 2022 年至 2029 年的预测期内,该市场将以 6.0% 的复合年增长率增长,预计将从 2021 年的 3.2773 亿美元增至 2029 年的 5.196 亿美元。
报告指标 |
细节 |
预测期 |
2022 至 2029 年 |
基准年 |
2021 |
历史岁月 |
2020(可定制 2019-2014) |
定量单位 |
收入(百万美元) |
涵盖的领域 |
按类型(膀胱炎、尿失禁、膀胱过度活动症、间质性膀胱炎、膀胱癌)、治疗类型(手术、药物、非手术)、最终用户(医院、诊所、门诊手术中心、其他)、分销渠道(直接、零售) |
覆盖国家 |
南非、沙特阿拉伯、阿联酋、埃及、以色列、科威特、中东和非洲其他地区 |
涵盖的市场参与者 |
在市场上运营的主要公司有美敦力、Laborie、波士顿科学公司、辉瑞公司、安斯泰来制药公司、KYORIN 制药有限公司(KYORIN Holdings, Inc. 的子公司)、百时美施贵宝公司、强生服务公司、Axonics, Inc.、默克公司、Viatris Inc.、Gaylord Chemical Company, LLC、Coloplast Corp、艾伯维公司、太阳制药工业有限公司、Zydus Group、Swati Spentose、Urovant Sciences 等。 |
中东和非洲膀胱疾病市场的市场定义
与膀胱相关的疾病包括膀胱炎(通常由于感染引起的膀胱炎症)、尿失禁(失去对膀胱的控制)、膀胱过度活动症(膀胱在错误的时间挤出尿液的一种情况)、间质性膀胱炎(导致膀胱疼痛和频繁、紧急排尿和膀胱癌的慢性问题)。
医生会进行各种检查来诊断膀胱疾病,包括 X 光检查、尿液检查和膀胱镜检查膀胱壁。疾病的治疗取决于问题的原因,治疗包括药物治疗、手术(严重情况下)和非手术治疗。
抗胆碱能药物是治疗膀胱过度活动症 (OAB) 的一线药物。OAB 是一种临床症状,其特征是尿意紧迫,难以推迟,通常每天排尿次数超过八次被认为是 OAB。抗胆碱能药物抑制逼尿肌上的毒蕈碱受体,从而降低膀胱收缩力。为了减少副作用,正在开发具有改进膀胱选择性和缓释配方的新药物。大多数较新的药物在减轻膀胱过度活动症的症状方面同样有效。
中东和非洲膀胱疾病市场动态
驱动程序
-
市场参与者采取的战略举措
膀胱疾病是一系列会影响日常身体活动的膀胱问题。最常见的膀胱疾病是膀胱炎、间质性膀胱炎、膀胱过度活动症、尿失禁和膀胱癌。大多数膀胱问题是由进入尿道的细菌感染引起的。
市场参与者在合作、收购、合作等方面采取的各种战略举措,使他们能够增加公司的产品组合,从而扩大市场,并进而提高客户对产品的需求,最终使市场参与者获得最大的收入。
-
老年人口不断增长
衰老是与膀胱相关疾病相关的一个主要风险因素。衰老会促使膀胱功能发生神经学、解剖学和生化变化,从而导致 OAB 的发生。膀胱过度活动症是老年人群中最常见的问题。老年人群患有各种膀胱相关问题和疾病,因此他们是慢性健康管理服务和解决方案的主要用户。
根据贵族研究,膀胱过度活动症的患病率在女性和男性中约为16.9%,约为16.0%,并且OAB的患病率随着年龄的增长而增长。然而,有治疗指南指定了首选的一线、二线和三线OAB治疗策略。膀胱疾病与痴呆等神经系统疾病有关,在这个年龄段,OAB对老年人来说非常具有挑战性。在过去的几十年里,全球老龄人口急剧增长。
-
未来几年研发投入将不断增加,新疗法将不断推出
如今,针对 OAB 和其他膀胱疾病,有各种治疗方案和创新疗法可供选择。许多生物制药和制药公司正在投资各种膀胱疾病的非常规疗法,预计这些疗法将在预测期内推出。
-
不同靶向疗法的组合
联合疗法比单一疗法更有效,且没有额外的副作用。联合疗法是难治性膀胱疾病患者的安全有效的替代疗法。结合不同的靶向治疗策略是缓解患者膀胱疾病的最佳方法。对于难治性患者,应考虑口服药物和行为疗法。有各种先进的靶向疗法可供选择,例如骶神经调节、逼尿肌内注射肉毒杆菌毒素 A 和经皮胫神经刺激。这些是先进的治疗方法,与口服药物相比更有效。
机会
-
新技术进步不断涌现
慢性病是全球发展中国家的主要死亡原因之一。因此,公共卫生从业者越来越重视慢性病的医疗管理。
膀胱疾病管理现在强调帮助患者进行各种自我护理,并提供一系列咨询服务,让患者了解自己的疾病并继续前进。这些疗法还可以帮助患者克服情感创伤和焦虑,这可能起到反保护机制的作用。
不断涌现的技术突破使医疗保健组织能够探索管理慢性膀胱疾病的创新服务和解决方案。由于他们不需要长期住院,因此也降低了成本和患者数量。此外,减少就诊和住院次数也为老年人带来了便利。考虑到这些有利的方面,许多组织和企业正在开发和实施最新的慢性病管理技术,以改善患者的治疗效果。
-
疾病管理计划的兴起
患有膀胱相关疾病的人通常需要更多的医疗服务,例如住院、看医生和处方药。患有多种慢性疾病的人寿命越来越长,再加上医疗费用的增加,促使人们制定更好的医疗保健计划。
疾病管理是一种试图改善护理同时降低慢性病护理费用的策略。疾病管理计划旨在增强某些慢性疾病(如膀胱疾病)患者的健康,同时降低对医疗服务的需求以及可避免的后果(如住院和急诊)的相关费用。这些计划还包括有关慢性病管理服务和解决方案的信息。由于全球慢性病患病率不断上升,这些计划变得非常受欢迎。政府和医疗保健组织已经组织和实施了针对这些慢性病的多种疾病管理计划,如膀胱癌、间质性膀胱炎和膀胱过度活动症管理计划。由于疾病管理计划可以显著改善自我护理习惯,并在很大程度上减少住院次数和住院时间,因此它们受到人们的更多关注。
限制/挑战
然而,由于需要进行各种检查,以及执行这些程序的高科技技术和方式,因此诊断疾病的难度以及治疗和诊断的成本很高。由于治疗中使用的先进技术设备成本高昂,因此程序的成本通常会升高,预计这会抑制市场增长。
本膀胱疾病市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响,分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关中东和非洲膀胱疾病市场的更多信息,请联系 Data Bridge Market Research 获取分析师简报。我们的团队将帮助您做出明智的市场决策,以实现市场增长。
COVID-19 对中东和非洲膀胱疾病市场的影响
COVID-19 对市场产生了积极影响。疫情期间的封锁和隔离使疾病管理和药物依从性变得复杂。因此,世界人口中各种治疗药物的使用量大幅增加。因此,疫情对这个市场产生了积极影响
近期发展
- 2020年3月,安斯泰来制药公司披露,美国FDA批准Myrbetriq®(米拉贝隆缓释片)用于治疗3岁以上体重35公斤及以上的儿科患者的神经源性逼尿肌过度活动(NDO),以及Myrbetriq®颗粒(米拉贝隆缓释口服混悬液)用于治疗3岁以上儿科患者的神经源性逼尿肌过度活动(NDO)。此次批准将增加该药物的全球影响力,提升公司收入
中东和非洲膀胱疾病市场范围
中东和非洲膀胱疾病市场分为类型、治疗类型、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场,并为用户提供有价值的市场概览和市场洞察,以便做出战略决策,确定核心市场应用。
类型
- 膀胱炎
- 尿失禁
- 膀胱过度活动症
- 间质性膀胱炎
- 膀胱癌
根据类型,中东和非洲膀胱疾病市场细分为膀胱炎、尿失禁、膀胱过度活动症、间质性膀胱炎、膀胱癌
治疗类型
- 外科手术
- 药物
- 其他的
根据产品,中东和非洲膀胱疾病市场细分为手术、药物和其他
最终用户
- 医院
- 诊所
- 门诊手术中心
- 其他的
根据最终用户,中东和非洲膀胱疾病市场细分为医院、诊所、门诊手术中心和其他
分销渠道
- 直接的
- 零售
根据分销渠道,中东和非洲膀胱疾病市场分为直接分销和零售分销
中东和非洲膀胱疾病市场区域分析/见解
对中东和非洲膀胱疾病市场进行了分析,并按国家、类型、治疗类型、最终用户和分销渠道提供了市场规模洞察和趋势,如上所述。
该市场覆盖的国家包括南非、沙特阿拉伯、阿联酋、埃及、以色列、中东其他地区和非洲。
沙特阿拉伯在市场份额和收入方面占据中东和非洲膀胱疾病市场的主导地位,并将在预测期内继续保持主导地位。这是由于该地区膀胱过度活动症的患病率很高,老年人口的不断增长也推动了市场的发展
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of the Middle East and Africa brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Bladder Disorders Market Share Analysis
Middle East and Africa bladder disorders market competitive landscape provides details about the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the company’s focus on the Middle East and Africa bladder disorders market.
Some of the major players operating in the Middle East and Africa bladder disorders market are Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Gaylord Chemical Company, L.L.C., Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, MEA vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
Customization Available
Data Bridge Market Research 是高级形成性研究领域的领导者。我们以向现有和新客户提供符合其目标的数据和分析为荣。报告可定制,包括目标品牌对其他国家市场了解的价格趋势分析(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以以您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(Factbook)中的数据,或者可以帮助您根据报告中提供的数据集创建演示文稿
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, PIPELINE ANALYSIS
5 MIDDLE EAST & AFRICA BLADDER DISORDER MARKET: REGULATIONS
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS
6 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET OVERVIEW
6.1 DRIVERS
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
6.1.2 GROWING GERIATRIC POPULATION
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT
6.2.2 PRODUCTS RECALLS FROM MARKET
6.3 OPPORTUNITIES
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS
6.4 CHALLENGES
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS
6.4.2 PATENT EXPIRY OF DRUGS
7 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TYPE
7.1 OVERVIEW
7.2 OVERACTIVE BLADDER
7.3 URINARY INCONTINENCE
7.4 CYSTITIS
7.5 INTERSTITIAL CYSTITIS
7.6 BLADDER CANCER
7.7 OTHERS
8 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATION
8.2.1 TOLTERODINE
8.2.2 MIRABEGRON
8.2.3 FESOTERODINE
8.2.4 OXYBUTYNIN
8.2.5 SOLIFENACIN
8.2.6 DARIFENACIN
8.2.7 TROSPIUM
8.2.8 OTHERS
8.3 SURGERY
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY
8.3.2 BLADDER REMOVAL
8.3.3 OTHERS
8.4 OTHERS
9 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT
9.3 RETAIL
10 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 OTHERS
11 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY GEOGRAPHY
11.1 MIDDLE EAST AND AFRICA
11.1.1 SAUDI ARABIA
11.1.2 SOUTH AFRICA
11.1.3 UAE
11.1.4 EGYPT
11.1.5 ISRAEL
11.1.6 REST OF MIDDLE EAST AND AFRICA
12 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MERCK AND CO. INC. (2021)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ASTELLAS PHARMA INC. (2021)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION (2021)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 VIATRIS INC. (2021)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 ABBVIE (2021)
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 AXONICS, INC. (2021)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BLUE WIND MEDICAL (2021)
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 COLOPLAST CORP. (2021)
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 LABORIE (2021)
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MEDTRONIC (2021)
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 PFIZER INC. (2021)
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 VALENCIA TECHNOLOGIES (2021)
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 SWATI SPENTOSE (2021)
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 UROVANT SCIENCES (2021)
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 ZYDUS GROUP (2021)
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 31 SAUDI ARABIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 32 SAUDI ARABIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 33 SAUDI ARABIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 SAUDI ARABIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 37 SOUTH AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 38 SOUTH AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 39 SOUTH AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 SOUTH AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 UAE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 UAE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 43 UAE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 UAE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 UAE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 UAE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 EGYPT BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 EGYPT BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 49 EGYPT MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 50 EGYPT SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 EGYPT BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 EGYPT BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 ISRAEL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 ISRAEL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 55 ISRAEL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 56 ISRAEL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 ISRAEL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 ISRAEL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 REST OF MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA BLADDER DISORDER MARKET
FIGURE 14 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, 2021
FIGURE 15 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 17 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021
FIGURE 19 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 21 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 23 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 25 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, 2021
FIGURE 27 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 31 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 32 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 35 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。